Bristol Myers Squibb Company $BMY Shares Sold by Arrowpoint Investment Partners Singapore Pte. Ltd.

Arrowpoint Investment Partners Singapore Pte. Ltd. lowered its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 78.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,806 shares of the biopharmaceutical company’s stock after selling 39,194 shares during the period. Arrowpoint Investment Partners Singapore Pte. Ltd.’s holdings in Bristol Myers Squibb were worth $583,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. waypoint wealth counsel purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at $1,194,000. Life Cycle Investment Partners Ltd purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at $34,406,000. Axxcess Wealth Management LLC raised its holdings in shares of Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after buying an additional 21,196 shares during the period. Oppenheimer Asset Management Inc. raised its holdings in shares of Bristol Myers Squibb by 6.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 531,538 shares of the biopharmaceutical company’s stock valued at $23,972,000 after buying an additional 32,005 shares during the period. Finally, M&G PLC raised its holdings in shares of Bristol Myers Squibb by 1.4% in the 3rd quarter. M&G PLC now owns 6,885,188 shares of the biopharmaceutical company’s stock valued at $309,833,000 after buying an additional 97,063 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analysts Set New Price Targets

BMY has been the topic of several research analyst reports. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Morgan Stanley reiterated an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Finally, UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $61.31.

Insiders Place Their Bets

In other news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.05% of the stock is currently owned by company insiders.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $56.71 on Friday. The stock’s 50-day moving average is $58.13 and its two-hundred day moving average is $56.52. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a market cap of $115.81 billion, a price-to-earnings ratio of 15.93, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter in the prior year, the business earned $1.80 EPS. Bristol Myers Squibb’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts forecast that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.